By Candice Choi

Don’t even think of putting the mask away anytime soon.

Despite the expected arrival of COVID-19 vaccines in just a few weeks, it could take several months — probably well into 2021 — before things get back to something close to normal in the U.S. and Americans can once again go to the movies, cheer at an NBA game or give Grandma a hug.

The first, limited shipments of the vaccine would mark just the beginning of what could be a long and messy road toward the end of the pandemic that has upended life and killed more than a quarter-million people in the U.S. In the meantime, Americans are being warned not to let their guard down.

“If you’re fighting a battle and the cavalry is on the way, you don’t stop shooting; you keep going until the cavalry gets here, and then you might even want to continue fighting,” Dr. Anthony Fauci, the nation's top infectious-disease expert, said last week.

This week, AstraZeneca became the third vaccine maker to say early data indicates its shots are highly effective. Pfizer last week asked the U.S. Food and Drug Administration for emergency authorization to begin distributing its vaccine, and Moderna is expected to do the same any day. Federal officials say the first doses will ship within a day of authorization.

But most people will probably have to wait months for shots to become widely available. The Pfizer and Moderna vaccines also each require two doses, meaning people will have to go back for a second shot after three and four weeks, respectively, to get the full protection.

Moncef Slaoui, head of the U.S. vaccine development effort, said on CNN on Sunday that early data on the Pfizer and Moderna shots suggest about 70% of the population would need to be vaccinated to achieve herd immunity — a milestone he said is likely to happen in May.

But along the way, experts say the logistical challenges of the biggest vaccination campaign in U.S. history and public fear and misinformation could hinder the effort and kick the end of the pandemic further down the road.

“It’s going to be a slow process and it’s going to be a process with ups and downs, like we’ve seen already,” said Dr. Bill Moss, an infectious-disease expert at Johns Hopkins University.

SHOTS IN ARMS

Once federal officials give a vaccine the go-ahead, doses that are already being stockpiled will be deployed with the goal of “putting needles in people’s arms” within 24 to 48 hours, said Paul Mango, a U.S. Department of Health and Human Services official involved in the Operation Warp Speed effort to develop COVID-19 vaccines.

Those first shipments are expected to be limited and will be directed to high-risk groups at designated locations, such as front-line health care workers at hospitals.

Federal and state officials are still figuring out exactly how to prioritize those most at risk, including the elderly, prison inmates and homeless people. By the end of January, HHS officials say, all senior citizens should be able to get shots, assuming a vaccine becomes available by the end of 2020.

For everyone else, they expect widespread availability of vaccines would start a couple of months later.

To make shots easily accessible, state and federal officials are enlisting a vast network of providers, such as pharmacies and doctor’s offices.

But some worry long lines won’t be the problem.

“One of the things that may be a factor that hasn’t been discussed that much is: ‘How many will be willing to be vaccinated?’” said Christine Finley, director of Vermont's immunization program. She noted the accelerated development of the vaccine and the politics around it have fueled worries about safety.

Even if the first vaccines prove as effective as suggested by early data, they won’t have much impact if enough people don’t take them.

NO MAGIC BULLET

Vaccines aren’t always effective in everyone: Over the past decade, for example, seasonal flu vaccines have been effective in about 20% to 60% of people who get them.

AstraZeneca, Pfizer, and Moderna say early trial data suggests their vaccine candidates are about 90% or more effective. But those rates could change by the time the studies end.

Also, the definition of “effective” can vary.

Rather than prevent infection entirely, the first COVID-19 vaccines might only prevent illness. Vaccinated people might still be able to transmit the virus, another reason experts say masks will remain crucial for some time.

Another important aspect of vaccines: They can take a while to work.

The first shot of a COVID-19 vaccine might bring about a degree of protection within a couple of weeks, meaning people who get infected might not get as sick as they otherwise would. But full protection could take up to two weeks after the second shot -- or about six weeks after the first shot, said Deborah Fuller, a vaccine expert at the University of Washington.

People who don’t understand that lag could mistakenly think the vaccine made them sick if they happen to come down with COVID-19 soon after a shot. People might also blame the vaccine for unrelated health problems and amplify those fears online.

“All you need is a few people getting on social media,” said Moss of Johns Hopkins University.

There's also the possibility of real side effects. COVID-19 vaccine trials have to include at least 30,000 people, but the chances of a rare side effect turning up are more likely as growing numbers of people are vaccinated.

Even if a link between the vaccine and a possible side effect seems likely, the distribution of shots might not be halted if the risk is deemed small and is outweighed by the benefits, said Dr. Wilbur Chen, a vaccine expert at the University of Maryland.

But Chen said public health officials will need to clearly explain the relative risks to avoid public panic.

Depending on whether the virus mutates in coming years and how long the vaccine’s protection lasts, booster shots, later on, may also be necessary, said Dr. Edward Belongia, a vaccine researcher with the Marshfield Clinic Research Institute in Wisconsin.

Belongia and many others say the coronavirus won’t ever be stamped out and will become one of the many seasonal viruses that sicken people. How quickly will vaccines help reduce the threat of the virus to that level?

“At this point, we just need to wait and see,” Belongia said.

——

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Share:
More In Science
Impact of Microplastics Found Deep in Human Lung Tissue
For the first time microplastics have been found deep in the lungs of living humans. The trace materials potentially came from everyday items such as plastic bottles and bags. Dr. Jessica Shepherd, the chief medical officer at Verywell Health, joined Cheddar News to talk about the report's findings and to discuss the possible risks people might face. "The study’s most important part is we need to decrease our pollution, and we need to think about different ways to consume outside of plastic," she said.
Operation Smile Works to Deliver Better Surgery Care Around the World
An estimated five billion people lack access to affordable and safe surgical care around the world. For World Health Day, Cheddar News spoke with Kristie Magee Porcaro of Operation Smile, a nonprofit organization assisting with cleft lip and palate surgeries, about how they work to better it around the globe.
Doctors, Medical Experts Divided on Second COVID-19 Booster
There has been notable disagreement in the medical community about a fourth COVID-19 vaccine dose. The FDA last week authorized a second booster dose for older and immunocompromised individuals, as some agency officials did not support the idea. The FDA made the decision without meeting with its advisory committee, as it had ahead of its recommendations on the previous COVID-19 vaccine doses. The CDC followed in the footsteps of the FDA and authorized a fourth dose as well. Reports say the agency also did not discuss the move with its own advisory team of vaccine experts. Now, a growing number of doctors are speaking out against the decisions - leaving people confused about whether they should get another vaccine dose. Dr. Julie Morita, a member of the CDC's advisory committee to the director, and the executive vice president of the Robert Wood Johnson Foundation, joins Cheddar News' Closing Bell to discuss.
Bringing Green Hydrogen to Scale
Talmon Marco, CEO of H2Pro, joins Cheddar Innovates to discuss how to bring environmentally friendly hydrogen to scale, and what this means for hydrogen's many use cases.
Patients Partner with Researchers on 'Long Covid'
Patients who have grown frustrated with lingering COVID-19 symptoms and unanswered questions are now not only the subjects of "long covid" research, but also partners in pushing this research forward. Harlan Krumholz, professor of medicine at Yale University, joins Cheddar News to discuss.
Need2Know: COVID Booster Updates, Ukraine, Third Sacramento Suspect Arrested
Catching you up on what you need to know on April 6, 2022, with updates on the FDA’s meeting to discuss a second COVID booster shot, more on the war in Ukraine, tornadoes on the Gulf coast, a third suspect arrested in connection to the mass shooting in California, Darwin’s lost notebooks mysteriously returned, and more.
Load More